Section Arrow
Quote
TGTX.NASDAQ
- TG Therapeutics
Quotes are at least 15-min delayed:2025/09/11 19:00 EDT
After Hours
Last
 32.39
-0.07 (-0.22%)
Bid
32
Ask
32.4
High 32.5 
Low 32 
Volume 82421 
Regular Hours
Last
 32.46
+0.635 (+2.00%)
Day High 
32.47 
Prev. Close
31.825 
1-M High
33.4 
Volume 
1.61M 
Bid
32
Ask
32.4
Day Low
31.85 
Open
31.98 
1-M Low
25.28 
Market Cap 
5.05B 
Currency USD 
P/E 83.75 
%Yield -- 
10-SMA 30.86 
20-SMA 29.57 
50-SMA 32.67 
52-W High 46.48 
52-W Low 21.16 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.38/2.27
Enterprise Value
5.30B
Balance Sheet
Book Value Per Share
1.74
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
329.00M
Operating Revenue Per Share
1.20
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GRIGRI Bio Inc.2.05+0.49+31.41%0.02PE
After Hours 1.84 -0.21 -10.24%
RXRXRecursion Pharmaceuticals4.85+0.31+6.83%-- 
After Hours 4.87 +0.02 +0.41%
SLXNSilexion Therapeutics Corp4.93+0.445+9.92%-- 
After Hours 4.91 -0.02 -0.41%
ADAPAdaptimmune Therapeutics plc0.0505-0.0003-0.59%-- 
After Hours 0.051 +0.0005 +0.99%
ROIVRoivant Sciences Ltd14.41+0.64+4.65%1.95PE
After Hours 14.32 -0.09 -0.62%
Quotes are at least 15-min delayed：2025/09/11 19:00 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T),and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.